A Guth Labs publication ↗
Back to News

Ten63 launches BEYOND-Alpha drug-design program with Chugai

Green glass molecular forms orbiting a cream abstract protein surface with a gold binding node.
AI-generated editorial illustration

Ten63 Therapeutics launched BEYOND-Alpha on November 18, naming Chugai Pharmaceutical as the first participant in its early-adopter program for computational drug design, according to its announcement.

Selected pharmaceutical companies will work with Ten63 to apply its BEYOND platform across difficult discovery targets. The program is intended to support multiple drug-discovery projects in parallel.

For Chugai, Ten63 will generate and rank molecular structures against targets nominated by the pharmaceutical company. Chugai receives the right to negotiate further research, development and commercialization terms, but those activities would require a separate definitive agreement.

BEYOND combines AI with physics-based simulation for generative chemistry. Ten63 positions it for targets with limited data or other obstacles to conventional small-molecule discovery. The announcement does not establish clinical effectiveness or approval of a resulting medicine.

The participation builds on Chugai Venture Fund’s investment in Ten63’s February financing. The new program gives Ten63 a route to test its computational platform across pharmaceutical portfolios while keeping initial design work separate from subsequent development and licensing decisions.

Sources and citations

Revision history

Published .